glp 1 agonist dpp 4 inhibitor dpp-4_inhibitors [TUSOM Mechanism of action of DPP-4

doi: 10.1016/S0140-6736(19)31149-3 71 RomeraICebrian-CuencaAAlvarez-GuisasolaFGomez-PeraltaFReviriegoJ

There is considerable interest in pairing GLP-1R agonism with glucagon receptor agonism to enhance both energy expenditure to maximize weight loss and potentially leverage the lipid oxidative properties of glucagon in hepatocytes to target nonalcoholic fatty liver disease

This risk is especially relevant for patients who were already at risk for deficiencies before starting treatment

In terms of tolerability, GLP-1RAs are commonly associated with GI side effects, which are often dose-dependent and time-limiting [55]

VSMC dysfunction can be defined as the occurrence of excessive proliferation, autophagy, fibrosis, senescence, and phenotypic transformation

M.SrinivasanS.MorinE